论文部分内容阅读
[目的]构建携带小鼠白细胞介素12腺病毒载体(AdCMVmIL-12),并观察其对H22肿瘤的抑瘤效果。[方法]构建重组质粒pdlE1SP1BmIL-12,并用该质粒与质粒pJM17共转染293细胞后包装而成AdCMVmIL-12,并进行酶切法鉴定。同时制备肿瘤动物,通过肿瘤内局部注射AdCMVmIL-12,观察其抗肿瘤作用。[结果]酶切鉴定显示构建正确,其病毒滴度为1.3×109pfu/ml;当病毒滴度为100MOI时,mIL-12浓度达到3417ng/1×106细胞/24h。动物实验表明,注射AdCMVmIL-12的小鼠,肿瘤体积明显小于对照组(P<0.01),生存期显著延长。[结论]构建AdCMVmIL-12成功,肿瘤内局部注射可发挥抗肿瘤作用。
[Objective] To construct recombinant adenovirus carrying interleukin-12 (AdCMVmIL-12) and to observe its anti-tumor effect on H22 tumor. [Method] The recombinant plasmid pdlE1SP1BmIL-12 was constructed and cotransfected into 293 cells with this plasmid and plasmid pJM17. The recombinant plasmid was packaged into AdCMVmIL-12 and identified by restriction enzyme digestion. At the same time, tumor animals were prepared and the anti-tumor effect was observed by intra-tumor injection of AdCMVmIL-12. [Results] Enzyme digestion showed that the titer was 1.3 × 109pfu / ml. When the virus titer was 100 MOI, the concentration of mIL-12 reached 3417ng / 1 × 106cells / 24h. Animal experiments showed that mice injected with AdCMVmIL-12, the tumor volume was significantly smaller than the control group (P <0.01), significantly prolonged survival. [Conclusion] The successful construction of AdCMVmIL-12 and intra-tumor injection can exert anti-tumor effects.